PORTAL HAEMODYNAMICS AND HEPATIC BLOOD FLOW
| Autor: | Hiroshi Hashimoto, Izumi Yokoyama, Katsuko Yamashita, Akiko Niimi, Masumi Akimoto, Yoko Kitamura, Atsushi Maeda, Yumiko Adachi, Takeshi Kurihara, Hisataka Ishiguro, Kouji Abe, Mihoko Obuchi, Mutsuo Shigemoto |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
medicine.medical_specialty
Hepatology business.industry Stomach Gastroenterology CCL4 Blood flow Inferior vena cava Nitric oxide chemistry.chemical_compound medicine.anatomical_structure Endocrinology medicine.vein chemistry Internal medicine medicine Teprenone Prostaglandin E2 Endothelin receptor business medicine.drug |
| Zdroj: | Journal of Gastroenterology and Hepatology. 11:978-984 |
| ISSN: | 0815-9319 |
| DOI: | 10.1111/j.1440-1746.1996.tb01857.x |
| Popis: | The major objective of the present study was to evaluate mechanisms by which teprenone, a gastric mucosal protecting agent, increases hepatic mucosal blood flow using male Sprague-Dawley rats. Hepatic and gastric blood flow was measured using a laser blood flow meter after administration of teprenone, dissolved in Tween 80, into the inferior vena cava. Teprenone itself increased hepatic and gastric blood flow. It also increased hepatic and gastric blood flow in rats with acute hepatic disorders due to carbon tetrachloride (CCL4) and improved histological changes, such as inflammatory cell infiltration and fatty changes in the liver. The fact that blood endothelin (ET) concentrations increased after administration of teprenone suggest that teprenone has great affinity for ET beta receptors and shows ET beta-receptor antagonist-like effects. Hepatic blood flow decreased after administration of N-nitro-L-arginine methyl ester, a nitric oxide (NO) synthetase inhibitor, suggesting that teprenone increase NO activity. Teprenone was thought to increase hepatic and gastric blood flow by different mechanisms, because it increased gastric mucosal prostaglandin E2 concentrations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text